Troy Quigg is an Oncology physician affiliated with Grand Rapids Community College. OpenAlex indexes 80 publications with 1,495 citations (h-index 17); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
35 Michigan St NE Fl 2
Grand Rapids, MI 495032514
Telephone
616-267-1925Provider last certified this registry record 8 May 2025.
Clinical trials
- Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
Sponsor: New York Medical College
- The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
Sponsor: Pediatric Transplantation & Cellular Therapy Consortium
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- JAZZ PHARMACEUTICALS INC.Program year202512 payments$20,884openpaymentsdata.cms.gov ↗
- Syndax Pharmaceuticals, Inc.Program year20252 payments
- Alexion Pharmaceuticals, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Alemtuzumab, Fludarabine, Melphalan, and Thiotepa As a Reduced-Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Inborn Errors of Immunity
Biology of Blood and Marrow Transplantation
2025 - Alemtuzumab, Fludarabine, Melphalan, and Thiotepa Conditioning for Transplantation in Inborn Errors of Immunity
Biology of Blood and Marrow Transplantation
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Tomasz Timek, MD
Grand Rapids Community College
Barbara Pickut, MD
Grand Rapids Community College
David Wohns, MD
Grand Rapids Community College
David Fermin, MD
Grand Rapids Community College
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”